Dr. Robin Jones on Olaratumab and Doxorubicin Combination in Patients with Soft Tissue Sarcoma
Robin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal antibody olaratumab in combination with doxorubicin in metastatic soft tissue sarcoma.
Robin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal antibody olaratumab in combination with doxorubicin in metastatic soft tissue sarcoma. The treatment was tested in a phase II trial, which randomized patients to either receive doxorubicin alone or doxorubicin in combination with olaratumab.
Jones says there was a significant difference in median overall survival in patients who received doxorubicin in combination with olaratumab compared to the monotherapy. He adds that patients had a median overall survival of 25 months in the combination arm, versus a median overall survival of 14.7 months in the doxorubicin alone arm.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
